GlaxoSmithKline in vaccines production alliance with Russia's Binnopharm

UK pharmaceutical giant GlaxoSmithKline (LSE: GSK) said on Friday that it has entered into an alliance with JSC Binnopharm, one of Russia’s largest biotech/pharma companies, for the local secondary manufacture of a number of GSK vaccines in Russia. Financial terms of the deal were not disclosed, but GSK said it would book sales of bulk vaccine supplied to the Russian firm.

Under this accord, GSK will supply bulk vaccine and provide technology and expertise to enable Binnopharm to undertake the secondary manufacture, including filling and packaging of a number of innovative GSK vaccines in accordance with international current Good Manufacturing Practice (cGMP) standards. Binnopharm will be responsible for gaining approval of its facilities to allow supply of GSK cervical cancer, rotavirus and pneumococcal vaccines under Binnopharm’s trade mark for the Russian public market.

The local manufacture of these vaccines should help Russia to modernize its National Immunization Calendar in the future, adding additional vaccination against highly prevalent infections such as human papillomavirus (HPV), rotavirus and Streptococcus pneumoniae.